SEP 380135
Alternative Names: SEP-380135Latest Information Update: 11 Mar 2025
At a glance
- Originator Sumitomo Dainippon Pharma; Sunovion Pharmaceuticals
 - Developer Sumitomo Pharma; Sumitomo Pharma America
 - Class Antidementias; Antipsychotics; Anxiolytics; Neuropsychotherapeutics
 - Mechanism of Action Undefined mechanism
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Phase I Agitation
 
Most Recent Events
- 06 Mar 2025 SEP 380135 is still in phase I trials in Agitation in USA (Otsuka Pharmaceuticals pipeline, March 2025)
 - 28 Aug 2024 No recent reports of development identified for phase-I development in Agitation in USA (PO)
 - 29 Jul 2022 SEP 380135 is still in Phase-I clinical trials in Agitation in USA (Sumitomo Pharma, Financial report Q1 FY2022)